drugset
drugset / Trial / NCT01462630

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

NCT01462630 ↗

Phase 2 Completed 29 enrolled Fox Chase Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2011-11-03
Primary completion
2019-01-02
Completion
2021-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — Oral

Indications

angiosarcoma